Anadys Pharmaceuticals and LG Life Sciences Announce Completion of Phase I/IIa Clinical Trial of ANA380 -LB80380- in Patients Chronically Infected with Hepatitis B Virus

May 11, 2004 - Anadys Pharmaceuticals Inc. and LG Life Sciences Ltd. of Seoul, Korea announce summary results from a completed Phase I/IIa, double-blind randomized, placebo-controlled dose escalation clinical trial of ANA380 (LB80380). Key findings from this study were reported at the 39th annual meeting for the European Association for the Study of the Liver (EASL) held in Berlin, Germany. The data demonstrated that oral administration of the compound over 28 days both was well tolerated and reduced HBV viral load by up to 4.0 log10 units, or by 99.99%, in the chronic hepatitis B virus (HBV) infected patients treated in the study. In this clinical study, four cohorts comprised of seven patients each received either placebo or ANA380 (LB80380) once daily for 28 days. The doses used were 30mg, 60mg, 120mg, and 240mg, which were administered through a dose escalation process.